Teni Boulikas, Ph.D., Founder, Chairman of the Board / CEO, R&D drug discovery California and Athens. Teni Boulikas is the inventor of Lipoplatin (liposomal cisplatin, Phase III clinical trials), Lipoxal (liposomal oxaliplatin, Phase II), LipoVIL12 (a liposomal virus expressing the human IL-12 gene, Phase II), Liporubicin (liposomal doxorubicin able to fuse with the membrane of the tumor cell, preclinical stage), liposomal paclitaxel and of numerous 4th generation liposomal drugs and liposomal peptides. Teni holds a B.Sc. degree in Chemistry from the Aristotelian University of Thessaloniki. He received his Ph.D. from the Southwestern Medical School in Dallas, Texas in Biochemistry. As a European Molecular Biology Organization (EMBO) postdoctoral Fellow for 2 years Teni studied nuclear matrix-chromatin interaction at the Swiss Institute for Experimental Cancer Research in Epalinges sur Lausanne for 5.5 years. He became Assistant Professor of Biochemistry and Head of the Laboratory of Monoclonal Antibodies at the University of Sherbrooke in Quebec with research activities on cloning methods, immunoglobulin genes, and monoclonal antibodies. Teni Boulikas then moved to the Linus Pauling Institute in Palo Alto as an Investigator and Director of the Laboratory of Molecular Carcinogenesis and later at the Institute of Molecular Medical Sciences (Palo Alto). He has over 80 publications.

Since 1997 Teni worked at Regulon (Mountain View, California and Athens, Greece) with research activities focusing on liposomal encapsulation of drugs. In 2003 he received a world patent on encapsulation of cisplatin, other structurally unrelated drugs and genes that formed the platform technology of Regulon. Teni Boulikas is the organizer of 8 International Conferences aiming at bridging the fields of Gene Therapy and Molecular Biology & Medicine, and Founder of the International Society of Gene Therapy and Molecular Biology. He has also the responsibility of managing patient data, promoting the clinical trials of Regulon in several countries and assembling the most exciting teams of oncologists as Regulon’s collaborators. Teni is the Editor of “Cancer Therapy” and “Gene Therapy and Molecular Biology” that can be accessed freely on the web sites www.Cancer-Therapy.org and www.gtmb.org.

Teni Boulikas, Ph.D.

Chairman of the Board and CEO, Regulon Inc. (USA)

and Regulon AE (Greece)

Afxentiou 7, Alimos, Athens 17455, Greece

Cellular: +30-6937-255-067;

Direct: +30-210-9847-995;

Main Office: +30-210-9858-454

Fax: +30-210-9858-453;

E-mail: teni@regulon.org

www.regulon.org

_______________________________________________

Labros Digonis, MBA – Chief Operating Officer

25 years experience in management and operations across several industries including engineering, insurance and telecommunications

MEng, National Technical University of Athens; MBA, Warwick Business School; Advanced Management Programme, INSEAD

E-mail: labros.digonis@regulon.org

_______________________________________________

 

Andrei Lyne, MBA, Senior VP Business Development based in New York. Former Managing Director at UBS involved in 40 transactions he knows well the Pharmaceutical business and how to sell a project. He has been familiarized with Regulon's technology for 2 years.

8 years at UBS Investment Bank focused on M&A transactions and capital raising for life sciences and healthcare corporates

BA, Oxford University; MBA, New York University’s Stern School of Business

Tel:  +1-917-484-1315 (Mobile)

E-mail: alyne@regulon.org

_______________________________________________

 

Ergin Yildiz is the CEO of Regulon Turkey, a subsidiary of Regulon, Inc. Ergin is also involved in business development of the USA Corporation. Former CFO of a Turkish Pharmaceutical Company he has been acquainted with Regulon's technology for more than 5 years. Ergin is the ambassador of Regulon's technology and regulatory approvals in this country but also responsible for sales of Lipoplatin in Turkey and business development in the region.

18 years finance experience, including 9 years in banking/financial services and 6 years in pharmaceuticals

BSc, Middle East Technical University (Ankara); MA, Bilkent University (Ankara)

Tel:  +90  533 733 6803.

E-mail: ergin.yildiz@regulon.org

 

_______________________________________________

Ted Doukas, Senior VP, Business Development based in USA (December 2005).

 

Ted has 20 years of experience in business development and real estate and he is one of the very successful persons of Hellenic origin in USA. Ted is responsible for the Corporate office of Regulon in Melville, New York.

Ted (Leftheris) Doukas

Senior VP, Business Development

Regulon, Inc.

535 Broad Hallow Road

Melville, New York 11747

Mobile 001-516-589-0599

tdblaircorp@gmail.com

_______________________________________________

Mirella Stergoudi, M.D., Medical Officer

Mirella is in charge for recruiting EU Oncology Centers of excellence in the pancreatic, lung, breast and gastric cancer pivotal clinical studies working closely with Teni.

 

Mirella Stergoudi, M.D.

Regulon

Afxentiou 7, Alimos, 17455 Athens, Greece

Mobile Tel international: +30-6946-328-128

Tel Office: +30-210-9858-454

Fax: +30-210-9858-453

mirella.stergoudi@regulon.org

www.regulon.org

_______________________________________________

 

Niko Boulikas is Vice President in Information Technology. He has a critical mind in presenting our technology and he masters electronic data management including data on clinical studies and presentation of documents. Niko also possesses web designing skills.

niko.boulikas@regulon.org